Thermo Fisher Scientific (TMO) Receivables (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Receivables for 18 consecutive years, with $11.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 11.0% year-over-year to $11.1 billion; the trailing twelve-month figure through Jun 2026 stood at $11.1 billion (up 11.0% YoY), and the FY2025 full-year result was $10.6 billion, up 9.77% from the prior year.
• Receivables rose to $11.1 billion in Q2 2026 per TMO's latest filing, from $10.9 billion in the prior quarter.
• Across five years, Receivables topped out at $11.1 billion in Q2 2026 and bottomed at $8.9 billion in Q3 2022.
• Historically, Receivables has averaged $9.8 billion across 5 years, with a median of $9.6 billion in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables surged 41.59% in 2022, then declined 0.59% in 2024.
• Over 5 years, Receivables stood at $9.4 billion in 2022, then increased by 2.51% to $9.7 billion in 2023, then fell by 0.39% to $9.6 billion in 2024, then grew by 9.77% to $10.6 billion in 2025, then gained by 5.42% to $11.1 billion in 2026.
• According to Business Quant data, Receivables over the past three periods registered $11.1 billion, $10.9 billion, and $10.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.